Kenneth Ryan
Nurse Practitioner · Jacksonville Beach, FLNPI 1053747493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 865 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 865 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biogen$2K
- Amgen$1K
- Lundbeck LLC$1K
- EMD Serono, Inc.$1K
- Novartis$956
- plus $11K from 53 others
What the payments were for
- Consulting fees$1,6478%
- Speaking & faculty fees$220%
- Food & beverage$19,01190%
- Education$3572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,038 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 11 | $76,085 |
| Nurtec OdtRimegepant Sulfate | 20 | $23,509 |
| RytaryCarbidopa/Levodopa | 11 | $17,803 |
| Memantine Hcl | 75 | $1,521 |
| Levetiracetam | 29 | $820 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 25 | $756 |
| Donepezil Hcl | 51 | $608 |
| Ropinirole Hcl | 22 | $437 |
| Gabapentin | 14 | $377 |
| Baclofen | 25 | $295 |
| Duloxetine Hcl | 24 | $265 |
| Buspirone Hcl | 18 | $169 |
| Fluoxetine Hcl | 15 | $143 |
| Escitalopram Oxalate | 12 | $87 |
| Sertraline Hcl | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $667 | $76,08511 claims |
| PfizerNurtec Odt | $596 | $23,50920 claims |
| Almatica Pharma LLCSertraline Hcl | $40 | $3513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Jacksonville Beach
- Joseph OralloJacksonville Beach$22K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.